SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision
ID: h-3487bc5fb2
Hypothesis

GBA1/GCase restoration to reduce alpha-synuclein pathology in Parkinson's disease

Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase activity, disrupts lysosomal lipid handling, and promotes alpha-synuclein accumulation through a feed-forward lysosomal stress loop.
🧬 GBA1🩺 neurodegeneration🎯 Composite 76%💱 $0.62▼17.3%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.86 (15%) Evidence 0.86 (15%) Novelty 0.48 (12%) Feasibility 0.82 (12%) Impact 0.84 (12%) Druggability 0.86 (10%) Safety 0.68 (8%) Competition 0.58 (6%) Data Avail. 0.86 (5%) Reproducible 0.78 (5%) KG Connect 0.50 (8%) 0.760 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
📖 Export BibTeXinteract with this hypothesis
Composite76%

🧪 Overview

Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase activity, disrupts lysosomal lipid handling, and promotes alpha-synuclein accumulation through a feed-forward lysosomal stress loop. The most actionable therapeutic strategy is GCase restoration or substrate correction in genotype-enriched GBA1-PD rather than broad TFEB activation alone.

🧬 Mechanism

No curated mechanism pathway recorded for this hypothesis.

⚖️ Evidence

⚖️ Evidence Matrix3 supports2 contradicts
Supports
GBA1 mutations strongly increase Parkinson's disease risk and support a causal genetic entry point.
Supports
GCase activity is reduced in Parkinson's substantia nigra, supporting lysosomal convergence beyond inherited GBA1 variants.
Supports
Alpha-synuclein can inhibit GCase, supporting a bidirectional pathological loop.
Contradicts
Reduced GCase activity in sporadic disease may be secondary to neurodegeneration or alpha-synuclein burden rather than the initiating cause.
Contradicts
Broad TFEB activation may rescue lysosomal stress without proving the GBA1-alpha-synuclein loop is the dominant therapeutic node.
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — GBA1

🧬 PDB 2V3D Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for GBA1 →

No DepMap CRISPR Chronos data found for GBA1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
↘
Falling
7d Momentum
▼ 2.5%
Volatility
Low
0.0029
Events (7d)
4
Price History
▼17.3%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
sourcev1_phase_c_backfill
origin_typedebate_synthesizer
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.
SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub